Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC). The study will be conducted in two parts; Safety lead-in phase and dose expansion phase.
Metastatic Triple-negative Breast Cancer
DRUG: Surufatinib|DRUG: Tislelizumab
Progression-free survival, time from initial treatment to the first documented disease progression or death due to any cause, whichever occurs first., approximately 1 years
Objective response rate (ORR), the proportion of patients with complete response or partial response, using RECIST v 1.1., approximately 1 years|Disease Control Rate (DCR), the proportion of patients with complete response, partial response or stable disease, using RECIST v 1.1., approximately 1 years|Overall survival (OS), time from initial treatment to death from any cause., approximately 1 years
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC). The study will be conducted in two parts; Safety lead-in phase and dose expansion phase.